Abstract
The B-cell depletion agent rituximab (RTX) is used in lymphoma and rheumatoid arthritis (RA), and there have been several case reports of an RTX-induced reactivation of hepatitis C virus in patients with lymphoma. However, there have been no papers detailing hepatitis C virus reactivation after RTX therapy in a patient with RA. Here we report a case of RTX-induced hepatitis C virus reactivation in a patient with RA. Physicians should be aware that a close follow-up of liver function and viral load is mandatory after RTX therapy in patients with RA and concomitant hepatitis C.
| Original language | English |
|---|---|
| Pages (from-to) | 65-67 |
| Number of pages | 3 |
| Journal | Journal of Microbiology, Immunology and Infection |
| Volume | 46 |
| Issue number | 1 |
| DOIs | |
| State | Published - 02 2013 |
| Externally published | Yes |
Keywords
- Hepatitis C virus
- Rheumatoid arthritis
- Rituximab